Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rocket Pharmaceuticals (RCKT) EBT: 2016-2025

Historic EBT for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Sep 2025 value amounting to -$52.0 million.

  • Rocket Pharmaceuticals' EBT rose 24.15% to -$52.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$248.2 million, marking a year-over-year increase of 7.45%. This contributed to the annual value of -$266.8 million for FY2024, which is 4.13% down from last year.
  • Per Rocket Pharmaceuticals' latest filing, its EBT stood at -$52.0 million for Q3 2025, which was up 26.89% from -$71.1 million recorded in Q2 2025.
  • Rocket Pharmaceuticals' EBT's 5-year high stood at -$33.8 million during Q2 2021, with a 5-year trough of -$71.9 million in Q2 2024.
  • In the last 3 years, Rocket Pharmaceuticals' EBT had a median value of -$64.2 million in 2023 and averaged -$64.5 million.
  • The largest annual percentage gain for Rocket Pharmaceuticals' EBT in the last 5 years was 27.53% (2021), contrasted with its biggest fall of 71.22% (2021).
  • Over the past 5 years, Rocket Pharmaceuticals' EBT (Quarterly) stood at -$43.9 million in 2021, then crashed by 55.43% to -$68.3 million in 2022, then climbed by 7.86% to -$62.9 million in 2023, then grew by 2.20% to -$61.5 million in 2024, then increased by 24.15% to -$52.0 million in 2025.
  • Its EBT stands at -$52.0 million for Q3 2025, versus -$71.1 million for Q2 2025 and -$63.5 million for Q1 2025.